2023 World Conference on Lung Cancer (Posters)-EP12.01. Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins)

EP12.01. Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins) - PDF(Slides)

Back to course

Pdf Summary

This case report highlights the efficacy of amivantamab, a treatment for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation (EGFRex20ins). The study involved a 57-year-old woman with a stage IVa cT4N3M1a lung adenocarcinoma diagnosed in August 2018. Initially treated with Afatinib, the patient experienced slow disease progression and clinical response. In March 2019, the patient began treatment with amivantamab as part of the CHRYSALIS clinical trial regimen. Despite a reduction in dose due to dermatological toxicity, the patient maintained a clinical response. A chest CT in May 2021 showed disease progression, leading to chest radiotherapy and subsequent single-dose radiosurgery for a brain lesion. In November 2021, the patient developed pleural effusion and underwent drainage and talcage. Further disease progression led to the discontinuation of amivantamab and the initiation of a new treatment regimen involving carboplatin and pemetrexed. The patient has since experienced good tolerance and clinical benefit with stable disease. The overall conclusion is that amivantamab demonstrated efficacy as a second-line treatment for EGFRex20ins NSCLC, even in the case of brain lesions. The treatment resulted in prolonged survival and maintained a good quality of life for the patient. This case report emphasizes the potential of amivantamab as a therapeutic option for patients with EGFRex20ins NSCLC. The keywords associated with the study are EGFRex20ins, EGFR-TKI, and amivantamab.

Asset Subtitle

Andrés Aguilar

Meta Tag

Speaker Andrés Aguilar

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

amivantamab

non-small cell lung cancer

NSCLC

EGFR exon 20 insertion mutation

EGFRex20ins

Afatinib

CHRYSALIS clinical trial

brain lesions

carboplatin

pemetrexed